Research Explores Halting Cholesterol Production for Better Health Outcomes
For many individuals with high cholesterol, the standard advice has long been to take statins, adjust dietary habits, and rely on the body's natural mechanisms to eliminate "bad" cholesterol. However, this approach does not work for everyone, particularly those with genetic predispositions like familial hypercholesterolemia (FH). FH is a genetic disorder that affects the body's ability to clear low-density lipoprotein (LDL) cholesterol, leading to its accumulation in the bloodstream and increasing the risk of cardiovascular events such as heart attacks.
The liver plays a crucial role in cholesterol management by utilizing LDL receptors to remove cholesterol from the blood. In individuals with FH, mutations in these receptors hinder their ability to function effectively, resulting in elevated cholesterol levels that can persist for years without noticeable symptoms. Alarmingly, approximately 1 in 200 adults carry this genetic mutation, often without awareness of their condition.
While statins have been the go-to treatment for lowering cholesterol, they primarily work by enhancing the activity of LDL receptors. For those with FH, especially those with severe forms of the condition, statins may not provide sufficient relief. This limitation has prompted researchers to consider an alternative strategy: what if we could prevent cholesterol from being produced in the first place?
A team at the Medical University of South Carolina (MUSC) has begun exploring this innovative approach by focusing on Apolipoprotein B (ApoB), a protein essential for the formation of LDL particles. By reducing the release of ApoB from the liver, researchers aim to decrease the overall production of cholesterol, circumventing the need for functional LDL receptors. This strategy could be particularly beneficial for those with impaired receptor function.
The research team utilized induced pluripotent stem cells (iPSCs) to create liver-like cells in the lab, allowing them to test potential compounds in a human-like environment. In their screening of approximately 130,000 compounds, they identified a group of molecules that significantly reduced the release of ApoB, cholesterol, and triglycerides. Stephen Duncan, D.Phil., who led the study, emphasized the importance of modeling the disease accurately to identify effective treatments.
Initial tests in standard mice showed limited results, likely due to differences in liver response between species. However, when the researchers used specially engineered "Avatar" mice with human liver cells, the compounds demonstrated the desired effects, lowering lipid levels in a manner consistent with human biology.
Further investigations revealed that their lead compound, DL-1, caused minimal changes in gene activity within liver cells, suggesting it does not broadly disrupt normal liver function. Instead, it appears to interfere with the processing and release of ApoB.
While these promising compounds are not yet available as treatments, the research highlights a potential paradigm shift in cholesterol management. By targeting cholesterol production rather than relying solely on clearance mechanisms, scientists are paving the way for new therapeutic options for individuals with familial hypercholesterolemia. This research underscores the importance of developing treatments that are effective in real human biology, rather than relying solely on animal models.
For the general population, traditional methods for managing cholesterol, including lifestyle changes and statins, remain valid. However, for those with severe forms of familial hypercholesterolemia, this research offers a glimmer of hope for more effective interventions that address the root cause of high cholesterol.




